Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2018-11-06 Report Publication Anno…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
EVOTEC AG TO REPORT FIRST NINE-MONTH 2018 RESULTS ON 13 NOVEMBER 2018
Report Publication Announcement Classification · 99% confidence The document is a short news release dated November 6, 2018, announcing that EVOTEC AG will report its financial results for the first nine months of 2018 on November 13, 2018, and will hold a conference call to discuss them. This is not the actual financial report (which would be an IR or 10-K), but rather an announcement about the future release of results and the associated conference call details. Since it specifically announces the upcoming release of financial results (for a period shorter than a year, i.e., nine months), it is closely related to an Earnings Release (ER) or Interim Report (IR). However, the primary function of this specific document is to announce the *date* of the results release and the conference call details. This fits best under the 'Report Publication Announcement' (RPA) category, as it is an announcement about the publication of financial results, or potentially 'ER' if the focus is on the upcoming earnings event. Given the structure (DGAP-News format, announcing the date of results and call details), RPA is a strong candidate, but since it directly pertains to the upcoming release of financial results, ER (Earnings Release) is also plausible if the definition is interpreted broadly. However, the definition for ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document contains *no* results, only the announcement of *when* the results will be released. Therefore, it is a Report Publication Announcement (RPA).
2018-11-06 English
Evotec AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (1552 characters) titled 'Evotec AG: Release according to Article 41 of the WpHG' and explicitly states 'Total Voting Rights Announcement'. It details a 'Conditional capital increase' and provides the 'New total number of voting rights' as of 31.10.2018. This type of announcement, focusing specifically on the total number of voting rights following a capital action, is a specific regulatory disclosure. While it relates to capital structure, the primary focus is the formal notification of voting rights count. This fits best under the general regulatory announcement category, RNS, as it is a specific regulatory disclosure that doesn't map perfectly to CAP (Capital/Financing Update) which usually covers the *intent* or *details* of the financing itself, or SHA (Share Issue/Capital Change) which is broader. Given the explicit focus on 'Total Voting Rights Announcement' under German law (WpHG), RNS is the most appropriate general regulatory filing code, as it is a mandatory disclosure distributed via DGAP.
2018-10-31 English
EVOTEC AND FERRING FORM STRATEGIC RESEARCH ALLIANCE IN REPRODUCTIVE MEDICINE AND WOMEN'S HEALTH
Regulatory Filings Classification · 100% confidence The document is a press release dated October 17, 2018, announcing a 'strategic research alliance' between Evotec AG and Ferring Pharmaceuticals regarding drug discovery and development. It contains key highlights, quotes from management, and company background information. It is not a full annual report (10-K), an interim report (IR), a formal earnings release (ER), or a transcript (CT). Since it is a general corporate announcement about a business development (a strategic alliance) that doesn't fit neatly into specific financial reporting categories like M&A (TAR) or Capital Change (CAP), it falls best under the general Regulatory Filings/News category, which is RNS, or potentially a miscellaneous corporate news item. Given the options, RNS (Regulatory Filings) is the most appropriate catch-all for significant, non-standard corporate news releases distributed via services like DGAP, especially when the content is a partnership announcement rather than a financial statement or management change.
2018-10-17 English
EVOTEC AND CELGENE EXPAND IPSC COLLABORATION TO INCLUDE ADDITIONAL CELL LINES
Environmental & Social Information Classification · 99% confidence The document is a short news release dated October 11, 2018, announcing an expansion of a collaboration between Evotec and Celgene, including a $6M payment. It is explicitly marked as 'DGAP-News' and distributed by 'DGAP – a service of EQS Group AG'. The content focuses on a specific business development (collaboration expansion and payment) rather than comprehensive financial results (like 10-K or IR) or a formal shareholder vote announcement. Since it is a general corporate announcement transmitted via a regulatory news service (DGAP), and it doesn't fit neatly into specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2018-10-11 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by The Goldman Sachs Group, Inc. in Evotec AG, referencing specific German securities law articles (WpHG). This directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which maps to the Major Shareholding Notification category (MRQ). Although the header mentions 'Voting Rights Announcements', the content structure is a standard major holding disclosure, which is best classified as MRQ.
2018-10-09 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages held by The Goldman Sachs Group, Inc. in Evotec AG, referencing specific sections of the German Securities Trading Act (WpHG). This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of a Major Shareholding Notification. The code for this is MRQ.
2018-10-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.